<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intensive antileukemic treatment was evaluated in 22 patients with secondary <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (sAML) and 14 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Results of combination remission-induction chemotherapy were compared with 126 patients contemporarily treated for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The duration of <z:mpath ids='MPATH_133'>hypoplasia</z:mpath>, induced by remission induction chemotherapy, tended to be longer in the sAML and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients when compared to de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but reached significance only for the duration of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>: 26 days versus 18 days (P less than 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>The number of hypoplastic <z:hpo ids='HP_0011420'>deaths</z:hpo> during remission-induction chemotherapy of patients with sAML and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was low </plain></SENT>
<SENT sid="4" pm="."><plain>Four of the 36 patients treated for sAML or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> died during hypoplastic phases induced by remission-induction chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>The complete remission (CR) rates were similar in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (67%), sAML (62%), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (64%) </plain></SENT>
<SENT sid="6" pm="."><plain>The CR rates of patients younger than 45 years were 75% for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 75% for sAML, and 71% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Remission rates in patients older than 45 years were identical in the three subgroups but significantly (P less than 0.005) inferior to those obtained in younger patients: 56%, 50%, and 57%, in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, sAML, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The remission duration without bone marrow transplant (BMT) was significantly shorter (P less than 0.01) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and sAML when compared with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Long-lasting CR in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and sAML was only obtained in three of the six patients treated with allogeneic BMT </plain></SENT>
<SENT sid="10" pm="."><plain>Intensive antileukemic therapy could be considered in young patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and life-threatening cytopenias or patients with sAML </plain></SENT>
</text></document>